Skip to Content

2010 Past Program

First International Conference on Cancer and the Heart

November 3-4, 2010

Wednesday, November 3

7:00 a.m.Registration and continental breakfast
8:00-8:25 a.m.


Welcome
Edward T.H. Yeh, M.D., MD Anderson Cancer Center, Houston, TX
James T. Willerson, M.D., President and Medical Director, Texas Heart Institute at St. Luke’ Episcopal Hospital, Houston, TX
Raymond DuBois, M.D., Ph.D., Provost and Executive Vice President, MD Anderson Cancer Center Houston, TX
8:20-9:40 a.m.
Session I: Defining clinical problems
Moderator: Michael S. Ewer, M.D., J.D.
8:20-8:40 a.m.
Cardiac dysfunction following cancer treatment: are the clinical enigmas falling into place?
Michael S. Ewer, M.D., J.D.
8:40-9:00 a.m.
Anthracyclines for adjuvant treatment in breast cancer: Recommendation from the heart
Sandra M. Swain, M.D.
9:00-9:20 a.m.
Long-term follow-up and long-term implications of cardiotoxic treatment of cancer
Thomas M. Suter, M.D.
9:20-9:40 a.m
.
Panel discussion
Joseph R. Carver, M.D., Michael S. Ewer, M.D., J.D., Thomas M. Suter, M.D., Sandra M. Swain, M.D.
9:40-10:00 a.m
.
Break
10:00-12:05 a.m.
Session II: Basic mechanisms
Moderator: Edward T.H. Yeh, M.D.
10:00-10:25 a.m.
Identification of the primary target of doxorubicin-induced cardiotoxicity
Edward T.H. Yeh, M.D.
10:25-10:50 a.m.
New insights on mechanisms of cardiotoxicity
Peter Liu, M.D.
10:50-11:15 a.m.
Mechanism of TKI-induced cardiotoxicity
Thomas L. Force, M.D.
11:15-11:40 a.m.
PDGFR/VEGFR in the pathogenesis of sutent-induced HTN and cardiomyopathy
Aarif Y. Khakoo, M.D.
11:40-12:05 p.m.
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Gabriel Lopez-Berestein, M.D.

12:05-1:00 p.m.

12:25-12:45 p.m.

Lunch
Lunch presentation: Heart failure to heart success: A patient’s story, the MD Anderson experience
Jean-Bernard Durand, M.D.
1:00-2:35 p.m.
Session III: LV Dysfunction
Moderator: Douglas B. Sawyer, M.D., Ph.D.
1:00-1:20 p.m.
Biomarkers in the prediction and management of chemotherapy-induced cardiotoxicity
Daniela Cardinale M.D., Ph.D.
1:20-1:40 p.m.
Heart failure in cancer patients unrelated to chemotherapy
Douglas B. Sawyer, M.D., Ph.D.
1:40-2:00 p.m.Effects of Aerobic Training to Improve Cardiovascular Function and Prevent Cardiac Remodeling After Cytotoxic Therapy in Early Breast Cancer
Lee W. Jones, Ph.D.
2:00-2:20 p.m.
Bridging the symptom management gap in cancer patients with heart failure
Anecita Fadol, Ph.D.
2:20-2:35 p.m.
Panel discussion
Daniela Cardinale M.D., Ph.D., Anecita Fadol, Ph.D., Lee W. Jones, Ph.D., Douglas B. Sawyer, M.D., Ph.D.
2:35-2:50 p.m.
Break
2:50-4:55 p.m.
Session IV: Basic mechanisms
Moderator: Tom Force, M.D
2:50- 3:15 p.m.Cancer-induced cardiomyopathy
Leslie A. Leinwand, Ph.D.
3:15-3:40 p.m.
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism
HQ Han, M.D., Ph.D.
3:40-4:05 p.m.Autophagy in cardiac plasticity and disease
Joseph A. Hill, M.D., Ph.D.
4:05-4:30 p.m.
Cardio-regenerative small-molecules
Jay W. Schneider, M.D., Ph.D.
4:30-4:55 p.m.
Role of cardiac progenitor cells in doxorubicin-induced cardiotoxicity
Jan Kajstura, Ph.D.
4:55-5:55 p.m.
Session V: Radiation
Moderator: S. Wamique Yusuf, M.D.
4:55-5:25 p.m.
Radiation therapy-induced cardiotoxicity
Sarah C. Darby, Ph.D.
5:25-5:45 p.m.
Clinical effects of radiation therapy
S. Wamique Yusuf, M.D.
5:45-5:55 p.m.
Panel discussion
Sarah C. Darby, Ph.D., David Cutter, M.B., S. Wamique Yusuf, M.D.


Thursday, Nov. 4, 2010

7:00 a.m.Registration and continental breakfast
8:00-8:45 a.m.


Session VI: Cardiologists' role in clinical trials
Panel discussion

Moderator: Charles E. Geyer Jr., M.D.
Daniela Cardinale M.D., Ph.D., Michael S. Ewer, M.D., J.D., Giorgio Minotti, M.D., Apostolia-Maria Tsimberidou, M.D., Ph.D.
8:45-10:00 a.m.
Session VII: Thrombocytopenia and hypercoagulability
Moderators: Cezar Iliescu, M.D. and Jean-Bernard Durand, M.D.
8:45-9:05 a.m.
Mechanisms of platelet-dependent hemostasis versus thrombosis
Michael Kroll, M.D.
9:05-9:25 a.m.
Endovascular procedures in cancer patients with chronic thrombocytopenia
Cezar Iliescu, M.D.
9:25-9:45 a.m.
Evaluating the biological efficacy of antiplatelet medication in cancer patients: genotype or phenotype?
Jean-Bernard Durand, M.D.
9:45-10:00 a.m.
Panel discussion
Jean-Bernard Durand, M.D., Cezar Iliescu, M.D., Michael Kroll, M.D.
10:00-10:20 a.m.Break
10:20-12:00 p.m.
Session VIII: Imaging
Moderator: Jose A. Banchs, M.D.
10:20-10:40 a.m.
Echocardiography in the prediction of left ventricular function
Juan Carlos Plana, M.D.
10:40-11:00 a.m.
Use of 2-D based strain for surveillance of chemotherapeutic induced cardiotoxicity in a pediatric population
John Lynn Jefferies, M.D., M.P.H.
11:00-11:20 a.m.
MRI as a tool to predict chemotherapy-induced cardiotoxicity
W. Gregory Hundley, M.D.
11:20-12:00 p.m.
Case presentations/panel discussion
Jose A. Banchs, M.D., Iyad Daher, M.D., W. Gregory Hundley, M.D., John Lynn Jefferies, M.D., M.P.H., Juan Carlos Plana, M.D.
12:00-1:00 p.m.
Lunch
Session IX: Poster Session
1:00-2:10 p.m.
Session X: Cardiac tumors: Diagnosis, imaging and treatment
Moderator: Monika J. Leja, M.D.
1:00-1:20 p.m.
Introduction to cardiac tumors: Imaging with computed tomography and echocardiography
Monika J. Leja, M.D.
1:20-1:40 p.m.
Imaging of cardiac tumors with cardiac MRI
Dipan J. Shah, M.D.
1:40-2:00 p.m.
Surgical treatment of cardiac tumors
Michael J. Reardon, M.D.
2:00-2:10 p.m.
Questions and Answers: Monika J. Leja, M.D., Michael J. Reardon, M.D.Dipan J. Shah, M.D.
2:10-3:10 p.m.

Session XI:  Defining the field of onco-cardiology
Moderator: Edward T.H. Yeh, M.D.
Panelists: Jean-Bernard Durand, M.D., Richard M. Steingart, M.D., Sandra M. Swain, M.D.
3:10-3:25 p.m.Break
3:25-5:05 p.m.
Session XI: Hypertension
Moderators: Aarif Y. Khakoo, M.D. and Elie N. Mouhayar, M.D.
3:25-3:45 p.m.
Common and uncommon blood pressure issues in cancer patients
Elie N. Mouhayar, M.D.
3:45-4:05 p.m.
Renal effects of anti-angiogenic therapy and their relation to hypertension
Abdulla Salahudeen, M.D.
4:05-4:25 p.m.
.
The role of HIF1 in cardiac function and how anti-VEGF therapy may affect it
Javid Moslehi, M.D.
4:25-4:45 p.m.
Guidelines for managing hypertension in patients receiving VEGF inhibitors
Michael L. Maitland, M.D., Ph.D.
4:45-5:05 p.m.

Case presentations/panel discussion
Ming Hui Chen, M.D., Aarif Y. Khakoo, M.D., Michael L. Maitland, M.D., Ph.D., Javid Moslehi, M.D., Elie N. Mouhayar, M.D., Abdulla Salahudeen, M.D.
5:05-5:10 p.m.
Closing comments
Edward T.H. Yeh, M.D.
 
Attendance will be limited to 150 participants. 14.00 AMA PRA Category 1 Credits™

For information contact Amy Heaton: aheaton@mdanderson.org or 713-745-6826.


 

Key to How Chemotherapy Causes Heart Failure

Key to how chemotherapy drug causes heart failure. See News Release

© 2014 The University of Texas MD Anderson Cancer Center